ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Jubilant, Wistar Institute to Evaluate Novel PAD4 Inhibitors to Reduce Severity of COVID-19
January 25, 2021Jubilant Therapeutics has announced a collaboration with The Wistar Institute to evaluate the ability of Peptidyl Arginine Deiminase 4 (PAD4) inhibitors provided by Jubilant Therapeutics to block neutrophil extracellular trap (NET) formation in the ... -
Anixa Biosciences Extends Agreement with Wistar Institute, Dmitry I. Gabrilovich, M.D., Ph.D.
February 22, 2019Anixa Biosciences has extended its collaboration with The Wistar Institute and Dmitry I. Gabrilovich, M.D., Ph.D. Gabrilovich, a forerunner in the field of myeloid-derived suppressor cell (MDSC) biology and .....
Pharma Sources Insight January 2025
